Selective Role for Mek1 but not Mek2 in the Induction of Epidermal Neoplasia

被引:43
作者
Scholl, Florence A. [1 ,2 ]
Dumesic, Phillip A. [1 ,2 ]
Barragan, Deborah I. [1 ,2 ]
Harada, Kazutoshi [3 ]
Charron, Jean [4 ]
Khavari, Paul A. [1 ,2 ]
机构
[1] Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA
[2] Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA USA
[3] Univ Yamanashi, Fac Med, Dept Dermatol, Chuo Ku, Yamanashi, Japan
[4] Univ Laval, Ctr Rech Cancerol, CHUQ, Hotel Dieu, Quebec City, PQ, Canada
关键词
RAS; ACTIVATION; MUTATION; KINASE; GROWTH;
D O I
10.1158/0008-5472.CAN-08-1963
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Ras/Raf/Mck/Erk mitogen-activated protein kinase pathway regulates fundamental processes in normal and malignant cells, including proliferation, differentiation, and cell survival. Mutations in this pathway have been associated with carcinogenesis and developmental disorders, making Mek1 and Mek2 prime therapeutic targets. In this study, we examined the requirement for Mek1 and Mek2 in skin neoplasia using the two-step 7,12-dimethylbenz(a)anthraacene/12-O-tetradecanoylphorbol-13-acetate (DMBA/TPA) skin carcinogenesis model. Mice lacking epidermal Mek1 protein develop fewer papillomas than both wild-type and Mek2-null mice following DMBA/TPA treatment. Mek1 knockout mice had smaller papillomas, delayed tumor onset, and half the tumor burden of wild-type mice. Loss of one Mek1 allele, however, did not affect tumor development, indicating that one Mek1 allele is sufficient for normal papilloma formation. No difference in TPA-induced hyperproliferation, inflammation, or Erk activation was observed between wildtype, conditional Mek1 knockout, and Mek2-null mice, indicating that Mek1 findings were not due to a general failure of these processes. These data show that Mek1 is important for skin tumor development and that Mek2 cannot compensate for the loss of Mek1 function in this setting. [Cancer Res 2009;69(9):3772-8]
引用
收藏
页码:3772 / 3778
页数:7
相关论文
共 50 条
[41]   MEK1 gene mutation in Japanese lung adenocarcinoma patients [J].
Sasaki, Hidefumi ;
Hikosaka, Yu ;
Okuda, Katsuhiro ;
Kawano, Osamu ;
Yukiue, Haruhiro ;
Yano, Motoki ;
Fujii, Yoshitaka .
MOLECULAR MEDICINE REPORTS, 2009, 2 (02) :153-155
[42]   Discovery of a cobalt complex with high MEK1 binding affinity [J].
Li, Hongyue ;
Zhou, Tongliang ;
Liu, Hui ;
Xu, Fengrong ;
Niu, Yan ;
Wang, Chao ;
Liang, Lei ;
Xu, Ping .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (10) :2221-2224
[43]   Evolutionary history of MEK1 illuminates the nature of deleterious mutations [J].
Andrianova, Ekaterina P. ;
Marmion, Robert A. ;
Shvartsman, Stanislav Y. ;
Zhulin, Igor B. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2023, 120 (34)
[44]   Trametinib in the treatment of multiple malignancies harboring MEK1 mutations [J].
Lian, Tong ;
Li, Changying ;
Wang, Haitao .
CANCER TREATMENT REVIEWS, 2019, 81
[45]   Structural insights into the recognition of phosphorylated Hop1 by Mek1 [J].
Xie, Changlin ;
He, Chao ;
Jiang, Yiyang ;
Yu, Hailong ;
Cheng, Lin ;
Nshogoza, Gilbert ;
Ala, Moududee Sayed ;
Tian, Changlin ;
Wu, Jihui ;
Shi, Yunyu ;
Li, Fudong .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2018, 74 :1027-1038
[46]   Deletion of MAP2K2/MEK2: a novel mechanism for a RASopathy? [J].
Nowaczyk, M. J. M. ;
Thompson, B. A. ;
Zeesman, S. ;
Moog, U. ;
Sanchez-Lara, P. A. ;
Magoulas, P. L. ;
Falk, R. E. ;
Hoover-Fong, J. E. ;
Batista, D. A. S. ;
Amudhavalli, S. M. ;
White, S. M. ;
Graham, G. E. ;
Rauen, K. A. .
CLINICAL GENETICS, 2014, 85 (02) :138-146
[47]   Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy [J].
Gannon, Hugh S. ;
Kaplan, Nathan ;
Tsherniak, Aviad ;
Vazquez, Francisca ;
Weir, Barbara A. ;
Hahn, William C. ;
Meyerson, Matthew .
MOLECULAR CANCER RESEARCH, 2016, 14 (02) :207-215
[48]   Azelnidipine inhibits esophageal squamous cell carcinoma proliferation in vivo and in vitro by targeting MEK1/2 [J].
Zhao, Lili ;
Zhang, Yuhan ;
Li, Ang ;
Lu, Xuebo ;
Li, Mingzhu ;
Yuan, Qiang ;
Yang, Ning ;
Zhao, Xiaokun ;
Li, Xin ;
Jiang, Yanan ;
Liu, Kangdong .
MOLECULAR THERAPY ONCOLYTICS, 2022, 27 :61-72
[49]   Antiviral Activity of the MEK1/2 Inhibitor Trametinib Against Lymphocytic Choriomeningitis Virus [J].
Mao, Wenting ;
Wan, Yi ;
Liu, Yang ;
Zhou, Minmin ;
Jia, Xiaoying ;
Hou, Yuxia ;
Wang, Wei .
JOURNAL OF MEDICAL VIROLOGY, 2025, 97 (03)
[50]   Erianin inhibits the proliferation and stemness of pancreatic cancer cells by interacting with MEK1/2 [J].
Zhu, Ying-Ru ;
Zhou, Sheng ;
Yang, Fu-Qin ;
Zhang, Hai-Shan ;
Luo, Jia-Xin ;
Xie, Fei ;
Liu, Dong-Dong ;
Lei, Yu-He ;
Deng, Li-Juan .
BIOCHEMICAL PHARMACOLOGY, 2025, 239